Dr Reddy's Laboratories Ltd
DRREDDYDr Reddy's Laboratories Ltd
DRREDDYPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
20.03 | 3.78 | 0.62% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.35 | 6.54 | 0.51% |
Forecast & Ratings
Detailed Forecast from 31 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines.
Peers
Compare with peersÂSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 15,863.30 | 14,367.60 | 14,436.20 | 15,829.50 | 18,193.70 | 19,386.90 | 22,099.90 | 25,762.20 | 28,920.10 | 31,011.50 | ||||||||||
Raw Materials | 3,854.20 | 3,819.80 | 4,081.00 | 4,770.20 | 5,530.70 | 6,869.40 | 7,796.10 | 7,586.80 | 8,889.20 | 22,024.20 | ||||||||||
Power & Fuel Cost | 315.20 | 330.10 | 329.30 | 329.10 | 314.80 | 320.50 | 390.50 | 477.40 | 533.90 | |||||||||||
Employee Cost | 3,117.40 | 3,106.80 | 3,214.90 | 3,356.20 | 3,380.20 | 3,629.90 | 3,885.80 | 4,646.60 | 5,030.10 | |||||||||||
Selling & Administrative Expenses | 3,007.00 | 3,287.10 | 2,106.10 | 2,235.30 | 2,184.20 | 2,398.30 | 2,976.10 | 3,199.30 | 3,710.20 | |||||||||||
Operating & Other expenses | 1,689.20 | 1,180.10 | 2,198.50 | 1,579.20 | 3,636.70 | 1,959.50 | 2,729.00 | 2,410.60 | 1,914.60 | |||||||||||
EBITDA | 3,880.30 | 2,643.70 | 2,506.40 | 3,559.50 | 3,147.10 | 4,209.30 | 4,322.40 | 7,441.50 | 8,842.10 | 8,987.30 | ||||||||||
Depreciation/Amortization | 938.90 | 1,026.60 | 1,077.20 | 1,134.80 | 1,163.10 | 1,228.80 | 1,165.20 | 1,250.20 | 1,470.00 | 1,518.80 | ||||||||||
PBIT | 2,941.40 | 1,617.10 | 1,429.20 | 2,424.70 | 1,984.00 | 2,980.50 | 3,157.20 | 6,191.30 | 7,372.10 | 7,468.50 | ||||||||||
Interest & Other Items | 82.60 | 63.40 | 78.80 | 88.90 | 98.30 | 97.00 | 95.80 | 142.80 | 171.10 | 234.20 | ||||||||||
PBT | 2,858.80 | 1,553.70 | 1,350.40 | 2,335.80 | 1,885.70 | 2,883.50 | 3,061.40 | 6,048.50 | 7,201.00 | 7,234.30 | ||||||||||
Taxes & Other Items | 728.20 | 261.60 | 403.60 | 385.80 | -140.30 | 931.90 | 878.90 | 1,541.20 | 1,623.10 | 1,895.50 | ||||||||||
Net Income | 2,130.60 | 1,292.10 | 946.80 | 1,950.00 | 2,026.00 | 1,951.60 | 2,182.50 | 4,507.30 | 5,577.90 | 5,338.80 | ||||||||||
EPS | 24.99 | 15.37 | 11.42 | 23.50 | 24.39 | 23.48 | 26.24 | 54.15 | 66.93 | 64.01 | ||||||||||
DPS | 4.00 | 4.00 | 4.00 | 4.00 | 5.00 | 5.00 | 6.00 | 8.00 | 8.00 | 8.00 | ||||||||||
Payout ratio | 0.16 | 0.26 | 0.35 | 0.17 | 0.20 | 0.21 | 0.23 | 0.15 | 0.12 | 0.12 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Dr Reddy's Laboratories Ltd | 19.17 | 3.78 | 0.62% |
Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
Cipla Ltd | 31.21 | 4.80 | 0.82% |
Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare DRREDDY with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Dr Reddy's Laboratories Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Parag Parikh Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7370% | Percentage of the fund’s portfolio invested in the stock 0.96% | Change in the portfolio weight of the stock over the last 3 months -0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 21/91 (+3) |
ICICI Prudential Value Discovery Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6680% | Percentage of the fund’s portfolio invested in the stock 1.40% | Change in the portfolio weight of the stock over the last 3 months 1.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 17/101 (+23) |
Nippon India Large Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5362% | Percentage of the fund’s portfolio invested in the stock 1.68% | Change in the portfolio weight of the stock over the last 3 months -0.23% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/76 (0) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Dr Reddy's Laboratories Ltd
Events
Dividend Trend
No Dividend Cuts
DRREDDY has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.62%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.24 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 16, 2024
Dividend/Share
₹40.00
Ex DateEx Date
Jul 16, 2024
Cash Dividend
Ex DateEx DateJul 11, 2023
Dividend/Share
₹40.00
Ex DateEx Date
Jul 11, 2023
Cash Dividend
Ex DateEx DateJul 11, 2022
Dividend/Share
₹30.00
Ex DateEx Date
Jul 11, 2022
Cash Dividend
Ex DateEx DateJul 9, 2021
Dividend/Share
₹25.00
Ex DateEx Date
Jul 9, 2021
Cash Dividend
Ex DateEx DateJul 13, 2020
Dividend/Share
₹25.00
Ex DateEx Date
Jul 13, 2020
Dr Reddys Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1300.85, up 2.25% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.85% on the day, quoting at 24419.55. The Sensex is at 80155.08, up 0.85%. Dr Reddys Laboratories Ltd has dropped around 1.6% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has dropped around 0.45% in last one month and is currently quoting at 22661.25, up 0.94% on the day. The volume in the stock stood at 29.93 lakh shares today, compared to the daily average of 6.7 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1301, up 2.14% on the day. Dr Reddys Laboratories Ltd is up 20.35% in last one year as compared to a 25.83% spurt in NIFTY and a 49.79% spurt in the Nifty Pharma index.The PE of the stock is 25.77 based on TTM earnings ending June 24.Powered by Capital Market - Live
Total revenue from operations stood at Rs 8,038.2 crore in Q2 FY25, up 16.45% as agasint Rs 6,902.6 crore posted in Q2 FY24. The revenue growth was primarily driven by growth in global generics revenues. Consolidated profit before tax rose marginally to Rs 1,917.4 crore in the second quarter of FY25 as against Rs 1916.7 crore posted in Q2 FY24. EBITDA grew 4.53% to Rs 2,280.3 crore in Q2 FY25 as against Rs 2,181.3 crore recorded in the corresponding quarter previous year. EBITDA margin reduced to 28.4% in Q2 FY25 as against 31.7% posted in Q2 FY24. Q2 FY25 gross margin stood at 59.6%, up 92 bps YoY, primarily of improvement in product mix and overhead leverage, partly offset by price erosion. Selling, general & administrative (SG&A) expenses for Q2 FY25 were at Rs 2,300.7 crore, YoY increase of 22.41%. Research & development (R&D) expenses in second quarter of FY25 stood at Rs 727.10 crore, 28.7% of revenue. During the quarter, revenues from Emerging Markets segment stood at Rs 1,455.4 crore, year on year increase of 19.65%, growth is attributable to market share expansion as well as new product launches. Revenues from India market during the quarter stood at Rs 1,397.1 crore, year on year increase of 17.79%, growth was led by revenues from the vaccine portfolio in-licensed from Sanofi, new products launched as well as price increases. During the quarter, company launched three new brands in the country, taking the year-to-date total to 16. Revenues from North America market was at Rs 3,728.1 crore, year on year rise of 17.32%. The growth was largely on account of increase in sales volumes, partly offset by price erosion. During the quarter, revenue from Europe market was at Rs 577 crore, year on year growth of 9.15%. The growth was primarily on account of leveraging the portfolio to launch new products, partly offset by price erosion. Revenues from Global Generics (GG) during the quarter grew 17.17% YoY to Rs 7,157.6 crore, primarily driven by improved sales volumes and new product launches. Sequential growth was primarily driven by Emerging Markets and Europe. Revenues from Pharmaceutical Services and Active Ingredients (PSAI) rose 19.51% to Rs 840.70 crore in Q2 FY25, mainly driven by momentum in base business volumes, growth in services business and revenues from new products. Free cash-flow for Q2 FY25 stood at Rs 200 crore while net cash surplus for the company was at Rs 1,890 crore as on 30 September 2024. Capital expenditure for second quarter of FY25 stood at Rs 740 crore. On half year basis, the company's net profit declined 8.28% to Rs 2,648.1 crore on 15.18% rise in total revenue from operations to Rs 15,734 crore in H1 FY25 over H1 FY24. Commenting on the results, co-chairman & MD, G V Prasad said, We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestle and completed the acquisition of Nicotinell and related brands. We will continue to drive efficiency, strengthen our core businesses, and positively impact patient lives through science and innovation. Meanwhile, the company's board approved fund infusion by way of investment in equity shares of Dr. Reddy's Laboratories LLC, Russia, a step-down wholly-owned subsidiary, upto an amount of Rs 600 crore. The fund will be used for working capital requirements. Dr Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products. The scrip rose 0.36% to close at Rs 1,272.55 on the BSE.Powered by Capital Market - Live
Net profit of Dr Reddy's Laboratories declined 15.28% to Rs 1255.70 crore in the quarter ended September 2024 as against Rs 1482.20 crore during the previous quarter ended September 2023. Sales rose 16.51% to Rs 8016.10 crore in the quarter ended September 2024 as against Rs 6880.20 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales8016.106880.20 17 OPM %25.9029.19 - PBDT2314.402292.20 1 PBT1917.401916.70 0 NP1255.701482.20 -15 Powered by Capital Market - Live
Aurigene Oncology, a wholly-owned subsidiary of Dr. Reddy's Laboratories has announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study - India's first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma. The study reported initial results from the first 8 patients. All patients were heavily pre-treated with median of 5.5 previous lines of treatment. Most patients had also received transplant in the past and had disease progression post-transplant. All 8 patients (100%) achieved clinical response, with 5/8 (62.5%) having achieved stringent complete response. With respect to safety, there were no high-grade events of Cytokine Release Syndrome (CRS) or neurotoxicity, in any of the patients. After reviewing the Phase 1 data, the Indian Regulatory Agency i.e., Drugs Controller General of India (DCGI), has given the nod to commence Phase 2 part of the trial. These results of Phase 1 were presented at the 21st annual meeting of the International Myeloma Society at Rio De Janeiro, Brazil, held recently. Ribrecabtagene autoleucel is an autologous anti-BCMA CAR-T therapy that utilizes a humanized single-domain antibody as the antigen binding domain and lentivirus as a vector. DRL-1801 for the clinical trials is manufactured at the CAR-T GMP manufacturing facility at Aurigene Oncology, Bangalore. Powered by Capital Market - Live
Dr. Reddy's Laboratories SA, Switzerland, (DRSA) a wholly owned subsidiary of  Dr Reddys Laboratories , has incorporated a new wholly-owned subsidiary in Denmark, named 'Dr. Reddy's Denmark ApS' on 04 October 2024. Accordingly, Dr. Reddy's Denmark ApS is a step-down wholly-owned subsidiary of the Company. Powered by Capital Market - Live
Dr Reddys Laboratories announced that its wholly owned subsidiary, Dr. Reddy's Laboratories SA, Switzerland has completed the acquisition of Haleon plc's global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy (NRT) category outside of the United States, through the purchase of shares of Northstar Switzerland SARL (Northstar Switzerland), a Haleon group company. The cost of acquisition is a payment of upfront cash consideration of GBP 458 million. As part of this acquisition, Northstar Switzerland along with its wholly owned subsidiaries North Star OpCo Limited (United Kingdom) and North Star Sweden AB (Sweden) are now wholly-owned step-down subsidiaries of the Company with effect from 30 September 2024. The acquired portfolio consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin America, and local market-leading brand names of the product - Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The portfolio is inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the United States. Powered by Capital Market - Live
Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 5 November 2024.Powered by Capital Market - Live
Dr Reddys Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 6505.2, down 0.95% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.06% on the day, quoting at 25392.05. The Sensex is at 83172.83, up 0.27%.Dr Reddys Laboratories Ltd has lost around 6.61% in last one month.Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has increased around 2.13% in last one month and is currently quoting at 23025.2, down 0.76% on the day. The volume in the stock stood at 3.35 lakh shares today, compared to the daily average of 3.4 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 6530.4, down 0.71% on the day. Dr Reddys Laboratories Ltd jumped 15.85% in last one year as compared to a 27.59% rally in NIFTY and a 47.81% spurt in the Nifty Pharma index.The PE of the stock is 26.6 based on TTM earnings ending June 24.Powered by Capital Market - Live
The domestic equity benchmarks traded with deep cuts in afternoon trade. The Nifty traded below the 24,900 level after hitting the day's high of 25,168.75 in early trade. Barring the Nifty Metal index, all the other sectoral indices on the NSE traded in red. At 13:30 IST, the barometer index, the S&P BSE Sensex, slumped 931.43 points or 1.14% to 81,262.79. The Nifty 50 index dropped 272.55 points or 1.08% to 24,872.55. In the broader market, the S&P BSE Mid-Cap index fell 1.06% and the S&P BSE Small-Cap index declined 0.68%. The market breadth was weak. On the BSE, 1,356 shares rose and 2,494 shares fell. A total of 117 shares were unchanged. Gainers & Losers: Asian Paints (up 1.04%), Bajaj Finance (up 0.97%), JSW Steel (up 0.73%), LTIMindtree (up 0.58%) and Hindustan Unilever (up 0.55%) were major Nifty gainers. State Bank of India (down 3.68%), HCL Technologies (down 2.56%), Bharat Petroleum Corporation (down 2.31%), ITC (down 2.23%) and Grasim Industries (down 2.21%) were major Nifty losers. Stocks in Spotlight: Dr Reddy's Laboratories shed 0.38%. The pharma major announced that it has received the establishment inspection report (EIR) from the United States Food & Drug Administration (USFDA) for its API manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh. Angel One slipped 2.23%. The company announced that its client base jumped 62.9% to 26.65 million in August 2024 as against 16.36 million recorded in August 2023. Matrimony.com shed 0.02%. The matchmaking services provider announced that its board has approved a share buyback of up to Rs 72 crore at a price of Rs 1,025 per equity share through tender offer route. VA Tech Wabag rallied 3.62% after the company announced that it has bagged a mega order worth $317 million (approximately Rs 2,700 crore) from the Saudi Water Authority (SWA). KEC International rose 1.15% after the company secured new orders of Rs 1,423 crore for design, supply and installation of 380 kV transmission lines in Saudi Arabia. Rites lost 0.03%. The company has been declared as L-1 bidder by UP State Bridge Corporation for consultancy services for construction of civil works in Uttar Pradesh. Global Markets: European and Asian stocks declined on Friday as investors shifted their focus to the upcoming U.S. payrolls report. The report is expected to shed light on the potential magnitude of a rate cut by the Federal Reserve later this month. Japan's household spending data for July rose 0.1% in real terms from the previous year as compared to a 1.4% fall in June. Data from the Japan's statistics bureau said the average household monthly expenditure for July 2024 was 290,931 yen ($2,031.35), up 3.3% in nominal terms from the previous year. Hong Kong's markets will be shut today due to Super Typhoon Yagi. Overnight in the U.S., all three major indexes declined amid ongoing concerns about the economic outlook. The S&P 500 fell by 0.3%, extending its losing streak to three days, while the Dow Jones Industrial Average dropped 0.54%. However, the tech-heavy Nasdaq Composite managed a modest gain of 0.25%. Adding to the economic uncertainty, ADP reported that private sector job growth in August was the weakest in over three and a half years. Companies hired only 99,000 workers, falling short of both the downwardly revised July figure and market expectations. This marked the weakest month for job growth since January 2021, according to data from the payrolls processing firm. Powered by Capital Market - Live
The inspection has been classified as voluntary action indicated (VAI) and has been closed accordingly said the firm. On 7 June 2024, USFDA had issued form 483 with four observations post inspection at its Andhra Pradesh facility. The good manufacturing practices (GMP) inspection was conducted from 30 May 2024 to 7 June 2024 at the API manufacturing facility. Dr Reddy's Labs is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products. The company's consolidated net profit shed marginally to Rs 1,392.40 crore in Q1 FY25 as against 1,405 crore posted in Q1 FY24. However revenue from operations jumped 13.9% YoY to Rs 7,672.70 crore in Q1 FY25. Shares of Dr.Reddy's Laboratories shed 0.23% to Rs 6,682on the BSE. Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 12.81%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 7.21% to 7.67%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 23.39%, vs industry avg of 15.28%